Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 44.5% in January

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 213,100 shares, a decline of 44.5% from the December 31st total of 384,100 shares. Currently, 1.1% of the company’s stock are short sold. Based on an average daily trading volume, of 562,300 shares, the short-interest ratio is currently 0.4 days.

Analysts Set New Price Targets

Separately, Raymond James reduced their target price on Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a report on Friday, November 8th.

Xilio Therapeutics Trading Down 2.9 %

NASDAQ XLO opened at $0.69 on Friday. The business’s 50 day moving average is $1.01 and its two-hundred day moving average is $0.94. Xilio Therapeutics has a 12-month low of $0.50 and a 12-month high of $1.93. The stock has a market capitalization of $30.55 million, a price-to-earnings ratio of -0.40 and a beta of -0.25.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. Equities analysts forecast that Xilio Therapeutics will post -1.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xilio Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in Xilio Therapeutics by 85.0% in the 3rd quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after buying an additional 155,337 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Xilio Therapeutics by 18.3% in the 2nd quarter. Renaissance Technologies LLC now owns 295,000 shares of the company’s stock valued at $280,000 after buying an additional 45,554 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Xilio Therapeutics in the 2nd quarter valued at approximately $32,000. Institutional investors and hedge funds own 54.29% of the company’s stock.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.